Anika Therapeutics (ANIK) Raw Materials (2011 - 2018)

Anika Therapeutics (ANIK) has 8 years of Raw Materials data on file, last reported at $13.2 million in Q3 2018.

• On a quarterly basis, Raw Materials rose 68.31% year-over-year to $13.2 million in Q3 2018; TTM through Sep 2018 was $13.2 million, a 68.31% increase from a year earlier, with the FY2017 full-year figure at $11.3 million, up 91.98% from the prior year.
• Raw Materials for Q3 2018 stood at $13.2 million, up from $12.6 million in the prior quarter.
• Over the last five years, Raw Materials for ANIK reached as high as $13.2 million in Q3 2018 and fell as low as $4.9 million in Q3 2015.
• Historically, Raw Materials has averaged $7.4 million across 5 years, with a median of $6.3 million in 2017.
• Across the five-year window, Raw Materials decreased 28.96% in 2015 and soared 100.13% in 2018, its largest moves.
• Year by year, Raw Materials stood at $6.2 million in 2014, then retreated by 6.2% to $5.8 million in 2015, then grew by 1.8% to $5.9 million in 2016, then soared by 91.98% to $11.3 million in 2017, then advanced by 17.22% to $13.2 million in 2018.
• Per Business Quant data, the three most recent Raw Materials figures were $13.2 million in Q3 2018, $12.6 million in Q2 2018, and $10.1 million in Q1 2018.